Nabriva Therapeutics’ Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections

14-Sep-2010 - Nabriva Therapeutics announced that a series of studies will be presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston. The studies show that the Company’s novel pleuromutilin antibiotic BC-3781 can be used orally as well as intravenously for the ...

Nabriva initiates Phase II of pleuromutilin antibiotic BC-3781

First patient enrolled in Phase II study of BC-3781 in patients with acute bacterial skin and skin structure infections (ABSSSI)

03-Jun-2010 - Nabriva Therapeutics announced that the first patients have been enrolled in a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections. BC-3781 is a pleuromutilin antibiotic being developed for the treatment of bacterial diseases such as skin and skin structure ...

Nabriva reports successful Phase I clinical trial for BC-3781

Studies presented at ECCMID alongside other papers relating to Nabriva’s pleuromutilin pipeline

14-Apr-2010 - Nabriva Therapeutics announced that it has successfully completed a series of Phase I clinical trials of its pleuromutilin antibiotic, BC-3781. BC-3781 is being developed for intravenous and oral treatment of skin and skin structure infections (SSSI) and community-acquired pneumonia (CAP). Data ...

Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781

29-Jul-2009 - Nabriva Therapeutics announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate the ...

Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781

24-Jul-2009 - Nabriva Therapeutics announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate the ...

Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer

01-Apr-2009 - Nabriva Therapeutics has announced the appointment of Dr David Chiswell as its Chief Executive Officer. Dr Chiswell has been involved with Nabriva since its foundation, having served as Chairman of the Supervisory Board for the past three years. Dr Chiswell is a highly experienced and respected ...

GLSV co-finances Sandoz spin-off Nabriva GmbH

02-Feb-2006 - Global Life Science Ventures (GLSV) announced the launch of Nabriva GmbH, a specialist antibiotic research and development company that has existed until now within Sandoz GmbH as the Vienna-based Antibiotic Research Institute (ABRI). GLSV is investing EUR6 million in a Series A financing round ...